{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-030618","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-08-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.940134+00:00","generated_at":"2026-06-11T02:01:37.515123+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"AgeX Therapeutics to acquire Serina in reverse merger; Serina holders to own ~75%","bullets":["AgeX stockholders expected to own ~25%, Serina holders ~75% on fully-diluted basis post-close.","AgeX to issue 3 warrants per 5 shares held (exercise $13.20, expiring July 31, 2025) and Incentive Warrants ($18, 4-year term).","Juvenescence (43.34% holder) commits $15M capital via warrant exercise; cancels out-of-the-money warrants.","Post-close board of 7 directors; Steve Ledger interim CEO, Randall Moreadith CSO, Tacey Viegas COO.","Closing conditions: reverse split to ~2.5M shares, stock price >=$12, AgeX cash >=$500k; termination fee $1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-030618","json":"https://secwatch.observer/filing/0001493152-23-030618.json","markdown":"https://secwatch.observer/filing/0001493152-23-030618.md","text":"https://secwatch.observer/filing/0001493152-23-030618.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223030618/0001493152-23-030618-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223030618/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T02:01:37.515123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"11820860f25e1520b73c15617237980f93e743c9","claim":"Serina Therapeutics, Inc. entered into Agreement and Plan of Merger and Reorganization with AgeX Therapeutics, Inc. (effective 2023-08-29).","evidence_excerpt":"On August 29, 2023, AgeX Therapeutics, Inc. (“ AgeX ”) entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Serina Therapeutics Inc., an Alabama corporation (“ Serina ”), and Canaria Transaction Corporation, an Alabama corporation and wholly owned subsidiary of AgeX (“ Merger Sub ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223030618/0001493152-23-030618-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"AgeX Therapeutics, Inc."},{"label":"Effective","value":"2023-08-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}